Things to Consider With Treatment Sequencing for Pediatric Atopic Dermatitis

EP: 1.Challenges and Unmet Needs in Treating Pediatric Atopic Dermatitis

EP: 2.Challenges and Emerging Solutions in Treatment for Age Groups: Addressing Disease Control, Safety, and Usability

EP: 3.Supporting Caregivers in Successful Long-Term Atopic Dermatitis Management: The Role of Dermatologists

EP: 4.Key Considerations for Evaluating Ruxolitinib Cream as a Treatment for Young Children

EP: 5.Balancing Effective AD Symptom Control with Long-Term Safety in New Therapies

EP: 6.Safety Considerations in Pediatric Atopic Dermatitis Treatments

EP: 7.Evaluating the Safety of Topical JAK Inhibitors in the Pediatric Population: Insights into Systemic Risks and Adverse Effects

EP: 8.Essential Monitoring Considerations for Prescribing Topical JAK Inhibitors in Younger Children

EP: 9.Balancing Education and Reassurance: Guiding Parents Through the Safety Profile of New Therapies

EP: 10.The Impact of Atopic Dermatitis on Quality of Life and the Role of New Therapies

EP: 11.Parental Frustrations with Current Treatment Options for Children with Atopic Dermatitis

EP: 12.The Need for Nonsteroidal Alternatives in Long-Term Atopic Dermatitis Care: A Focus on Pediatric Patients

EP: 13.Potential Role of Ruxolitinib Cream in Managing Pediatric Atopic Dermatitis: A Perspective on Use in Ages 2–11

EP: 14.Enhancing Treatment Adherence: The Impact of Convenience and Topical JAK Inhibitors on Real-World Outcomes

Now Viewing

EP: 15.Things to Consider With Treatment Sequencing for Pediatric Atopic Dermatitis

EP: 16.Identifying and Addressing Critical Gaps in Pediatric Atopic Dermatitis Treatment with Ruxolitinib Cream

EP: 17.Benefits of Nonsteroidal Topical JAK Inhibitors for Moderate Pediatric Atopic Dermatitis

EP: 18.Treatment Escalation and De-escalation Strategies in Pediatric AD: Positioning Ruxolitinib Cream in Clinical Decision-Making

EP: 19.Future Perspectives: Can Innovative Topical Therapies Like Ruxolitinib Reduce Systemic Treatment Dependency in Pediatric AD?

EP: 20.The Future of Pediatric Atopic Dermatitis Treatment and Emerging Therapies

EP: 21.Evaluating the Impact of Topical JAK Inhibitors on Pediatric Atopic Dermatitis Guidelines

EP: 22.Regulatory Challenges and Clinical Differentiators for Pediatric Atopic Dermatitis Treatments

EP: 23.Implementation Factors Affecting Ruxolitinib Adoption in Pediatric Dermatology Practice

EP: 24.Current Unmet Needs and Emerging Solutions in Atopic Dermatitis Management

This news content has been independently developed and is not endorsed by the American Academy of Dermatology.

Video content above is prompted by the following:

• When initiating treatment for a child with moderate AD, what factors influence your decision to start with certain therapies over others?
• Where do you see the biggest gap in the current treatment paradigm for pediatric AD, and how might ruxolitinib cream help fill that gap?
• For children with moderate disease who may not yet require systemic therapy (or who aren’t eligible), what advantages would a nonsteroidal, topical Janus kinase inhibitor offer over current options?
• How do you determine when to escalate or de-escalate treatment in pediatric AD, and where might ruxolitinib cream fit in that decision-making process?
• Looking ahead, do you think new topical treatments like ruxolitinib could reduce the need for systemic therapies in certain pediatric patients? Why or why not?